When was NOVOREX founded?

NOVOREX was founded in 2020 and raised its 1st funding round 6 years after it was founded.

Where is NOVOREX located?

NOVOREX is headquartered in Seongnam-si, South Korea.

How many employees does NOVOREX have?

As of Aug 31, 2026, the latest employee count at NOVOREX is 3.

Is NOVOREX a funded company?

NOVOREX is a funded company, having raised a total of $***** in its 1st and only funding round, a Series B round on Apr 22, 2026.

When was the latest funding round of NOVOREX?

NOVOREX's latest funding was a $***** Series B round on Apr 22, 2026, with participation from 7 investors. Its primary sector is Neurology. In South Korea, the Neurology sector has seen $64.3M in funding in 2026 to date.

Where does NOVOREX rank among its competitors?

NOVOREX ranks 1501st amongst 3799 active competitors, of which 1267 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of NOVOREX?

NOVOREX's top competitors include Jazz Pharmaceuticals, BeiGene and Biogen. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

NOVOREX - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of drugs for the treatment of cancer and central nervous diseases. The company develops GPCR-targeted small-molecule drugs using artificial intelligence to treat neurological disorders, cognitive function, and cancer.

Website: novorex.com
Email ID: *****@novorex.com
Phone Number: +82 **********

Key Metrics

Founded Year

2020

Location

Seongnam-si, South Korea

Stage

Series B

Total Funding

$15M in 1 round

Latest Funding Round

Series B, Apr 22, 2026, $*****

Investors

Solidus Investment & 7 more

Ranked

1501^st among 3799 active competitors

Employee Count

3 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3540 more

View NOVOREX's full profile

NOVOREX has raised a total funding of $15M over 1 round. Its latest funding round was a Series B round on Apr 22, 2026 for $*****. 7 investors participated in its latest round. NOVOREX has 8 institutional investors.

Here is the list of recent funding rounds of NOVOREX:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 22, 2026	3669266	Series B	2006239	1058790	8770412	2941876

Access funding benchmarks and valuations. Sign up today!

View details of NOVOREX's funding rounds and investors

The founders of NOVOREX are Mansoo Kim, Jungu Ji and Seonghun Ahn. Woosung Son is the CEO of NOVOREX.

Here are the details of NOVOREX's key team members:

Mansoo Kim: Co-Founder of NOVOREX.
Jungu Ji: Co-Founder of NOVOREX.
Seonghun Ahn: Co-Founder of NOVOREX.
Woosung Son: CEO of NOVOREX.
Contact Info: 1 email address

View details of NOVOREX's Founder profiles and Board Members

NOVOREX's employee count trend

NOVOREX has 3 employees as of Aug 26. Here is NOVOREX's employee count trend over the years:

Uncover NOVOREX's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NOVOREX include Jazz Pharmaceuticals, BeiGene and Biogen. Here is the list of Top 10 competitors of NOVOREX, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
4th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
5th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
7th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
1501st	NOVOREX 2020, Seongnam-si (South Korea), Series B	Developer of drugs for the treatment of cancer and central nervous diseases	$15M	Solidus Investment, Hyundai Venture Investment ... & 6 others	36/100